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Abstract
Background: Because of the high resistance rate of fibrosarcomas against cytotoxic agents clinical
chemotherapy of these tumors is not established. A better understanding of the diverse modes of
tumor cell death following cytotoxic therapies will provide a molecular basis for new
chemotherapeutic strategies. In this study we elucidated the response of a fibrosarcoma cell line to
clinically used cytostatic agents on the level of gene expression.
Methods: HT1080 fibrosarcoma cells were exposed to the chemotherapeutic agents doxorubicin,
actinomycin D or vincristine. Total RNA was isolated and the gene expression patterns were
analyzed by microarray analysis. Expression levels for 46 selected candidate genes were validated
by quantitative real-time PCR.
Results:  The analysis of the microarray data resulted in 3.309 (actinomycin D), 1.019
(doxorubicin) and 134 (vincristine) probesets that showed significant expression changes. For the
RNA synthesis blocker actinomycin D, 99.4% of all differentially expressed probesets were under-
represented. In comparison, probesets down-regulated by doxorubicin comprised only 37.4% of all
genes effected by this agent. Closer analysis of the differentially regulated genes revealed that
doxorubicin induced cell death of HT1080 fibrosarcoma cells mainly by regulating the abundance
of factors mediating the mitochondrial (intrinsic) apoptosis pathway. Furthermore doxorubicin
influences other pathways and crosstalk to other pathways (including to the death receptor
pathway) at multiple levels. We found increased levels of cytochrome c, APAF-1 and members of
the STAT-family (STAT1, STAT3), while Bcl-2 expression was decreased. Caspase-1, -3, -6, -8, and
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-9 were increased indicating that these proteases are key factors in the execution of doxorubicin
mediated apoptosis.
Conclusion: This study demonstrates that chemotherapy regulates the expression of apoptosis-
related factors in fibrosarcoma cells. The number and the specific pattern of the genes depend on
the used cytotoxic drug. The response rates on the gene expression level, i.e. the number of genes
regulated by the drugs actinomycin D, doxorubicin and vincristine, correlate to the clinical
effectiveness of the drugs. Doxorubicin seems to exert its cytotoxic mechanism by regulating
genes, which are involved in several different apoptosis regulating pathways. The exact knowledge
of the genes affected by the drugs will help to understand the diverse modes of soft tissue sarcoma
cell death in response to cytotoxic therapies.
Background
With only 1% of all solid malignancies and more than 50
sub entities soft tissue sarcomas are rare and heterogene-
ous [1,2]. Adequate complete surgical resection in combi-
nation with radiotherapy is the mainstay of therapy
resulting in a 50% to 80% 5-year survival rate. Recent
chemotherapy studies revealed a high fraction of resistant
soft tissue sarcoma. Response rates above 15% [3-5]
within all variant histological subtypes were reported only
for doxorubicin (adriamycin), actinomycin D and ifosfa-
mide [6,7].
Generally, two main classes of drug resistance can be dis-
tinguished. Tumor cells are either primarily resistant to
chemotherapeutic drugs (intrinsic resistance), or some of
the cells respond to chemotherapy at the first treatment
but the remaining cells recur later to form a multidrug-
resistant tumor (acquired resistance) [8]. A single mecha-
nism or a distinct pathway cannot explain the effective-
ness of a cancer drug. In carcinomas multiple mechanisms
of drug resistance have been characterized on the molecu-
lar level [9,10]. These include the overexpression of the
genes p53 [11-14], MDR1 (multidrug resistance gene 1)
[14-16], MRP1 (multidrug resistance-associated protein),
or the induction of DNA repair [14]. In addition various
regulatory genes targeted for genetic alterations during
tumorigenesis may also influence cellular sensitivity to
chemotherapeutic drugs. These genetic alterations involve
tumor suppressor genes, oncogenes, cell cycle regulators,
transcription factors, growth factor receptors, DNA repair
factors and cell death regulators. Only little is known
about the molecular basis of drug resistance in soft tissue
sarcomas [17-20]. Comprehensive knowledge of the
expression changes induced by cytostatic drugs should be
useful for examining the molecular basis of drug resist-
ance. The specific expression and response profiles of a
cell line established from a distinct tumor may ultimately
allow to design improved therapeutic regimes with the
aim to circumvent drug resistance [20]. In this study, we
used Affymetrix microarrays to monitor mRNA expression
changes in an established fibrosarcoma cell line. The cells
were treated with the two widely used cytotoxic drugs dox-
orubicin and actinomycin D. In a parallel analysis, cells
were treated with vincristine as a cytostatic drug of very
low response in human soft tissue sarcomas for
comparison.
Methods
Cell Culture and RNA-preparation
HT-1080 (human fibrosarcoma cells, cell line CCl 121
from ATCC) were cultured in modified Eagle's medium
supplemented with 10% FCS in 15 cm Petri dishes. Semi-
confluent cultures were treated with 0,5 µg/ml doxoru-
bicin for 6 h or 24 h, 0.1 µg/ml actinomycin D or 0.4 µg/
ml vincristine for 24 h. Total RNA was purified from the
cells using Trizol reagent (Life Technologies), as specified
by the manufacturer. RNA integrity was assessed using the
Agilent 2100 Bioanalyzer (Agilent Technologies).
Oligonucleotide microarray analysis
For microarray analyses we used the Affymetrix Gene Chip
platform employing a standard protocol for sample prep-
aration and microarray hybridization that has been
described in detail previously [20,21]. Briefly, total RNA
was converted into double-stranded cDNA using an oligo-
deoxythymidine primer containing the T7 RNA polymer-
ase binding site (5'- GCATTAGCGGCCGCGAAAT-
TAATACGACTCACTATAGGGAGA – (dT)21V-3') (MWG
Biotech) for first strand synthesis. After generation of dou-
ble-stranded cDNA from the first-strand cDNA, bioti-
nylated cRNA was synthesized by in vitro transcription
using the BioArray High Yield RNA Transcript Labeling Kit
(Enzo Diagnostics). Labeled cRNA was purified on RNe-
asy columns (Qiagen), fragmented and hybridized to HG-
U133A microarrays (Affymetrix). The arrays were washed
and stained according to the manufacturer's recommen-
dation and finally scanned in a GeneArray scanner 2500
(Agilent).
Array images were processed to determine signals and
detection calls (Present, Absent, Marginal) for each
probeset using the Affymetrix Microarray Suite 5.0 soft-
ware (MAS 5.0; statistical algorithm). To determine
expression changes induced by doxorubicin andBMC Cancer 2005, 5:74 http://www.biomedcentral.com/1471-2407/5/74
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vincristine, arrays were scaled across all probesets to an
average intensity of 1000 to compensate for variations in
the amount and quality of the cRNA samples and other
experimental variables of non-biological origin. To deter-
mine target genes of actinomycin D, which induced rather
strong alterations in gene expression, scaling to externally
added polyA+ spike controls proved to be more approri-
ate. Pairwise comparisons of treated versus control sam-
ples were carried out with MAS 5.0, which calculates the
significance (change p-value) of each change in gene
expression based on a Wilcoxon ranking test. To limit the
number of false positives, we restricted further target iden-
tification to those probesets, which received at least one
present detection call in the treated/control pair.
Probesets exhibiting a signal log2 ratio >1.32 and a
change p-value <0.001 or a signal log2 ratio <-1.32 and a
change p-value >0.999 (corresponding to 2.5 fold up- or
down-regulation) were identified by filtering using the
Affymetrix Data Mining Tool 3.0 (Table 1). The normal-
ized raw data set of this analysis can be found at the Glo-
bal Environment Outlook portal at http://
www.ncbi.nlm.nih.gov/geo (GEO accession code:
GSE2238).
Real-time RT-PCR and data processing
Real-time RT-PCR was performed using Taqman low den-
sity arrays on a ABI PRISMR 7900HT Sequence Detection
System (Applied Biosystems). cDNA was generated with
random primers using the High Capacity cDNA Archive
Kit (Applied Biosystems) using 5 µg total RNA in a 20 µl
reaction volume. Approximately 400 ng cDNA was used
per port (48 wells) representing 24 different Assays-on-
Demand in two replicates. Transcript levels were deter-
mined in duplicate reactions by the ∆∆ Ct method using 5
transcripts as an internal reference [see Additional file 1].
GO and pathway analysis
Statistically overrepresented Gene Ontology (GO) terms
within target gene lists were identified by the hypergeo-
metric distribution implemented in the GO Browser of
Spotfire DecisionSite for Functional Genomics (Spotfire).
Specific signaling pathways were identified using the soft-
ware package Pathway Assist™ (Stratagene).
Results
Microarray analysis revealed the differential gene expres-
sion patterns of fibrosarcoma cells treated with cytostatic
drugs. Based on the Affymetrix statistical change and
detection algorithm, a stringent combination of filter cri-
teria was used to identify significantly changed genes,
while keeping the false postive rate at a minimum (Table
1; see Material and Methods for details). As indicated in
Figure 1, the three different drugs proved to affect remark-
ably different numbers of probesets. After actinomycin D
treatment for 24 hours, 3309 probesets showed differen-
tial expression levels. Of these, a vast majority of 99.4%
were under-represented, confirming the general inhibi-
tory activity of actinomycin D on RNA polymerization. In
comparison, treatment with doxorubicin for 24 hours
affected a lower number of probesets (1019) than actino-
mycin D, while 62.6 % of these probesets were up-regu-
lated. Treatment with doxorubicin for 6 hours resulted in
just 3 differentially expressed targets, indicating that a
shorter incubation period leads to a minor response. Vin-
cristine treatment for 24 hours led to the identification of
134 differentially regulated probesets. Of these, 87
probesets were increased and 47 decreased. Interestingly,
the numbers of probesets, which were regulated by the
different drugs, correlate with the clinical effectiveness of
these three cytostatics. Vincristine, the agent with the low-
est impact on gene expression has the weakest effect on
the growth of fibrosarcomas in-vivo [22], while actinomy-
cin D and especially doxorubicin appeared to have a
much stronger effect on cell growth in soft tissue sarcoma
[23,24].
The Venn diagram shows that there is only a limited over-
lap of the genes affected by the three different drugs (Fig-
ure 1). Thirteen probesets representing 12 genes were
common targets of all three drugs; however, while these
targets were all down-regulated by actinomycin D, doxo-
rubicin and vincristine consistently up-regulated 4 of
those transcripts. Analyzing the up- and down-regulated
transcripts in more detail (Figure 1B), it is evident that 43
out of the 44 probesets common to doxorubicin and vin-
cristine target lists are affected in the same direction (29
up, 14 down). Vincristine and actinomycin D targets lists
share 33 targets, but concordant regulation was restricted
to 18 down-regulated probesets. Similarly, doxorubicin
and actinomycin D shared 264 common targets, while
only 3 up- and 208 down-regulated transcripts were
affected in the same direction. The scatter plots and more-
over the dendogramm illustrate these quantitative find-
ings (Figures 3, 4).
To get an overview of the biological processes affected by
the three different drugs, we classified the regulated
probesets to the various categories as defined by the gene
ontology annotations (Table 2) [25]. Analyzing the distri-
Table 1: Hierarchical filter analysis for selection of substantially 
altered expression levels
Filter 1 change: increased – decreased
Filter 1 change: increased – decreased
Filter 3 SLR*<1.32 and Change p-value >0.999 and at least one 
Present (P) Detection call in control or treated array
SLR*>1.32 and Change p-value <0.001 and at least one 
Present (P) Detection call in control or treated array
* SLR: Signal log RatioBMC Cancer 2005, 5:74 http://www.biomedcentral.com/1471-2407/5/74
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A+B: Patterns of genes affected by Actinomycin D, Doxorubicin and Vincristin Figure 1
A+B: Patterns of genes affected by Actinomycin D, Doxorubicin and Vincristin. (A) Venn diagram showing the 
overlap of probesets regulated by the three different drugs in HT1080 cells after 24 h of treatment. Numbers in brackets refer 
to the total number of affected probesets. (B) Cross table showing the number of concordant probesets up- or down-regu-
lated by the three different compounds.
A:
31
251
20
13
   70 
Vincristine
   (134)
Doxorubicin
    (1019)
724
Actinomycin D 
   (3309)
3025
B:
Doxorubicin Actinomycin D
Up Down Up Down
N 638 381 20 3289
Up 87 29 0 0 15 Vincristine
Down 47 1 14 0 18
Up 638 3 53 Doxorubicin
Down 381 0 208BMC Cancer 2005, 5:74 http://www.biomedcentral.com/1471-2407/5/74
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A-D: Induction of HT1080 cells by doxorubicin, actinomycin D and vincristine Figure 2
A-D: Induction of HT1080 cells by doxorubicin, actinomycin D and vincristine. HT1080 cells were treated with 0,5 
µg/ml doxorubicin for 6 h or 24 h (A, B), 0.1 µg/ml actinomycin D (C) or 0.4 µg/ml vincristine (D) for 24 h. Expression profiles 
of the untreated control (x-axis) and the drug-induced (y-axis) HT1080 cells are shown as bivariate scatterplots of 14,500 
genes from the microarray. The values are corrected intensities representing levels of expression for the DNA elements of the 
microarray. Colour legend: red: P-P = present in baseline (x-axis) and present in experiment (y-axis) black: P-A = present in 
baseline but absent in experiment green: A-P = absent in baseline but present in experiment yellow: A-A, A-M, M-A, M-M = 
absent or marginal in baseline or experiment
A: doxorubicin 6hr    B: doxorubicin 24hr
   C: actinomycin D 24hr  D: vincristine 24hrBMC Cancer 2005, 5:74 http://www.biomedcentral.com/1471-2407/5/74
Page 6 of 16
(page number not for citation purposes)
Overall expression patterns of 4137 genes in fibrosarcoma cells treated with doxorubicin (6 h and 24 h), actinomycin D and  vincristine (each 24 h) Figure 3
Overall expression patterns of 4137 genes in fibrosarcoma cells treated with doxorubicin (6 h and 24 h), actin-
omycin D and vincristine (each 24 h). Horizontal rows represent individual genes; vertical columns represent individual 
samples. Colour range: Brightest red: Signal Log Ratio (SLR)> = 2 (indicates expression level above untreated cells); brightest 
green: SLR< = 2 (indicates expression level below untreated cells); black: SLR = 0 (indicates unchanged expression). The den-
dogram at the top of the matrix indicates the degree of similarity between tumor samples; the dendogram at the left side indi-
cates the degree of similarity among the selected genes according to their expression patterns.
-0.285 1
1 4137 35
Actinomycin D versus
untreated fibrosarcoma
cells
Vincristine versus
untreated fibrosarcoma
cells
Doxorubicin 24hrs
versus untreated
fibrosarcoma cells
Doxorubicin 6hrs
versus untreated
fibrosarcoma cellsBMC Cancer 2005, 5:74 http://www.biomedcentral.com/1471-2407/5/74
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Pathway-analyses based on decreased (green) and increased (red) genes detected in fibrosarcoma cells after 24 h treatment  with doxorubicin Figure 4
Pathway-analyses based on decreased (green) and increased (red) genes detected in fibrosarcoma cells after 
24 h treatment with doxorubicin. Results shown for apoptosis. Signaling pathway maps were identified using the soft-
ware package Pathway Assist. A minimum of 3 interacting genes is the required criteria for creation of a map (Software: Path-
way Assist™ Stratagene).BMC Cancer 2005, 5:74 http://www.biomedcentral.com/1471-2407/5/74
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bution of the targets to the various categories, we found a
significant overrepresentation in several categories that
depended on the drug used.
The biochemical functions of the genes in the expression
profile of the actinomycin D-treated fibrosarcoma cells
are diverse and include cell proliferation, cell cycle,
metabolism and others. Altered expression of the metab-
olism genes especially include nucleotide metabolism
(Table 2, column 1). Increased expression of cell prolifer-
ation and cell cycle genes were found after doxorubicin
treatment (column 2) while cells treated with vincristine
significantly overexpressed metabolism (especially nucle-
otide metabolism) genes (column 3).
Figure 4 represents pathways analyses based on decreased
and increased genes detected after 24 h treatment with
doxorubicin. Because killing of cancer cells by cytotoxic
therapies is predominantly mediated by triggering apoto-
sis in target cells, we focused on differential expressed
genes involved in cell death pathways.
There are two known cellular pathways, which lead to the
initiation of apoptosis [9,10]. The 'extrinsic/exogenous'
pathway (activated by death receptors, a subgroup of the
TNF receptor super family) and the 'intrinsic/endogenous'
pathway (a mitochondrial pathway controlled by mem-
bers of the Bcl-2 family) [26]. Most cytotoxic drugs, which
activate apoptosis, lead to the activation of the mitochon-
drial pathway. The expression of Bcl-2 may be responsible
for resistance to apoptosis induced by cytotoxic drugs, and
down-regulation of Bcl-2 sensitizes cells to doxorubicin
[27]. Doxorubicin-induced cell death is mediated by the
tumor suppressor p53. Remarkably, none of the drugs
tested in this study changed the expression level of p53.
Nevertheless, the drugs showed an influence on the
expression levels of other important genes, which are
involved in the intrinsic pathway (Figures 4, 5, 6). Cyto-
chrome c expression showed an increased level, and Bcl-2
showed a decreased level after doxorubicin treatment in
the fibrosarcoma cell line (Figure 4).
The apoptotic protease activating factor 1 (APAF1) was
up-regulated. APAF1 plays a central role in the cell death
machinery and is an activator of the caspases-cascade,
especially of caspase-9. Several members of the protease
family of caspases (cysteine dependent aspartate-specific
proteases) play a major role in apoptosis [10]. We found
up-regulated expression of caspase-1, caspase-3, caspase-
6, caspase-8 and caspase-9 (Figures 4, 5, 6). Increased
expression levels were found for two members of the
STAT-family (signal transducer and activator of transcrip-
Table 2: Distribution of the probesets affected by the various drugs to categories of the GO biological categories.
actinomycin D doxorubicin vincristine HG-U133A
Total number of probesets in target list 3309 1019 134 22215
Total number of probesets with annotated biological process 2158 702 87 13704
Physiological process
Cell growth and/or maintenance 827*** 262* 40* 4701
Cell proliferation 367*** 123*** 14 1576
Cell cycle 290*** 87*** 10 1085
Death 151*** 39 5 682
Metabolism 1507*** 429 50 8247
Regulation of biological process
Regulation of programmed cell death 87*** 22 2 400
Anti-apoptosis 41*** 5 2 152
Positive regulation of apoptosis 50* 10 0 231
Regulation of signal transduction 49* 13 3 242
I-κ B kinase/NF-κ B cascade 29* 7 2 123
Regulation of metabolism 509*** 121 22* 2398
Protein biosynthesis 54*** 6 1 156
Nucleobase, nucleoside, nucleotide synthesis 455*** 111 21* 2232
Negative regulation of nucleobase, nucleoside, nucleotide and nucleid acid metabolism 49*** 8 2 180
DNA metabolism 15** 1 0 50
Based on the 'Gene Ontology Standard Vocabulary' the probesets affected by actinomycin D, doxorubicin and vincristine were sorted according 
to the 'Biological Process' into the indicated major categories. The number of probesets with annotated biological processes is given and 
corresponds to approximately 66% of the probesets affected. The two major categories investigated are shown in bold and subcategories of the 
previous process are indicated by offset. As a reference the distribution of all annotated probesets of the HG-U133A array to the same 
categories are listed. Genes significantly overrepresented in the target lists were identified using the statistics (hypergeometric distribution) 
implemented in the 'GO browser' of Spotfire DecisionSite for Functional Genomics. *, ** and *** indicate p-values of p < 0.05, p < 0.01, and p < 
0.001, respectively.BMC Cancer 2005, 5:74 http://www.biomedcentral.com/1471-2407/5/74
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tion): STAT1 and STAT3, too. These proteins play roles in
several different apoptotic pathways (Figures 3A, D).
Increased expression of STAT1 triggers tumor progression
and leads to down-regulation of apoptosis [28]. STAT3
plays a key role in signal transduction and promotion of
apoptosis [29]. In addition the protein is involved in
interleukin signaling. Altered expression of the inter-
leukin-family includes up-regulation of IL-6, a mediator
of anti-apoptotic effects and drug-resistance mechanisms.
In addition to the regulation of apoptosis activating path-
ways doxorubicin regulates an anti-apoptotic pathway.
The insulin-like growth factor 1 receptor (IGF-1R) is an
important signaling molecule in cancer cells. IGF-1R was
prominently targeted for up-regulation by doxorubicin
treatment.
In addition we found expression changes in genes, which
are involved in the extrinsic pathway. Fas/APO-1/CD95 is
a member of the tumor necrosis factor (TNF) receptor
super family. We found altered expression level of differ-
ent FAS family mediators. PTPN13 (increased) activates
directly caspase-8. The Fas-associated factor 1 (FAF1) was
down-regulated. FAS and the tumor necrosis factor (TNF)
super family of receptors induce apoptosis by recruiting
adaptor molecules through death domain interactions.
The central adaptor molecule for these receptors is the
death domain-containing protein FADD. FADD binds a
death domain on a receptor or an additional adaptor and
recruits caspases to the activated receptor [30,31]. FADD
was up-regulated in this experiment. In contrast we found
decreased expressions of FAIM and FAIM2, Fas-associated
apoptosis inhibitory molecules.
Looking at non-apoptotic pathways, we found an influ-
ence of doxorubicin on the pathway of skeletal myogene-
sis. PCAF (p300/CBP-associated factor), a co-activator of
the tumor suppressor p53, was increased. This finding is
in line with the results of others [32-34]. Furthermore the
transcription factor MEF2 (Myocyte enhancer factor-2),
that controls critical cellular processes including prolifer-
ation, differentiation and survival, was increased.
Analyzing the proliferation activating pathways control-
led by EGF and Ras we found altered expression of the
GTPase activating protein Rasa-1 (Ras p21 protein
activator-1). Rasa-1 is involved in the signal transduction
pathway of several growth factors and in the down-regu-
lating of different proteins of the Ras GTPase super family
[34]. In addition we found the up-regulated expression of
SOS1, which encodes for a Ras-specific exchange factor.
Furthermore H-RAS was up-regulated, which is a member
of the Ras GTPase super family.
To confirm the changes observed by microarray, we meas-
ured the expression of 46 representative apoptosis genes
that were in part differently expressed in these experi-
ments by quantitative RT-PCR using Taqman low density
arrays (for details see Material and Methods). Overall the
success rate of validation by RT-PCR was 62%. For
securely detected probestes (pp-call) in the doxorubicin-
experiment the success rate of validation was 78% [see
Additional file 1].
Discussion
Soft tissue sarcomas are very heterogeneous regarding
their presentation, growth behavior and response to ther-
apeutic interference. The presentation and behavior of
these tumors depend on location and histological charac-
teristics [24]. Standard therapy consists of complete surgi-
cal resection in combination with adjuvant radiotherapy.
Because of low response rates chemotherapy is largely
restricted to clinical trials. Hence, novel chemotherapy
protocols that overcome resistance would be highly valu-
able [3].
In this study we analyzed the differential gene expression
pattern of fibrosarcoma cells after treatment with the three
cytostatics doxorubicin, actinomycin D and vincristine.
First of all we found that the number of significantly
altered probe sets directly correlates with the known clin-
ical response rates of the three cytostatics. Treatment with
vincristine shows a very low response rate in soft tissue
sarcomas (134 altered probe sets). Doxorubicin (1.109
altered probe sets) and actinomycin D (3.309 altered
probe sets) are more effective chemotherapeutic drugs
with a significantly higher response rate in these tumors
(Figure 1) [35]. This correlation suggests that a strong
impact on gene expression leads to a high clinical effec-
tiveness. Thus the microarray analysis of the differential
gene expression might be a valuable tool to judge the clin-
ical effectiveness of newly developed drug candidates.
The alkaloid vincristine inhibits mitosis by inhibiting
tubulin polymerization and thus by preventing met-
aphase spindle formation. In addition there are hints that
vincristine interferes with DNA and RNA synthesis (Figure
1). Because of response rates lower than 5% vincristine is
not well established in the clinical treatment of soft tissue
sarcomas [36,37]. Vincristine seems to influence the
expression of several genes of different pathways rather
than of distinct genes of specific pathways.
With response rates between 15% and 20% actinomycin
D is one of the most widely used chemotherapeutic agents
in the treatment of soft tissue sarcomas [38]. Actinomycin
D is known to inhibit cell proliferation in a rather non-
specific way by forming a stable complex with double-
stranded DNA and thus inhibiting DNA-primed RNA syn-
thesis [39-42]. In conformance with this inhibitory effect
on transcription we found 3.289 probe sets decreased andBMC Cancer 2005, 5:74 http://www.biomedcentral.com/1471-2407/5/74
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Pathway-analyses based on decreased (green) and increased (red) genes detected in fibrosarcoma cells after 24 h treatment  with doxorubicin Figure 5
Pathway-analyses based on decreased (green) and increased (red) genes detected in fibrosarcoma cells after 
24 h treatment with doxorubicin. Results shown for caspases. Signaling pathway maps were identified using the soft-
ware package Pathway Assist. A minimum of 3 interacting genes is the required criteria for creation of a map (Software: Path-
way Assist™ Stratagene).BMC Cancer 2005, 5:74 http://www.biomedcentral.com/1471-2407/5/74
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Pathway-analyses based on decreased (green) and increased (red) genes detected in fibrosarcoma cells after 24 h treatment  with doxorubicin Figure 6
Pathway-analyses based on decreased (green) and increased (red) genes detected in fibrosarcoma cells after 
24 h treatment with doxorubicin. Results shown for FAS-signalling. Signaling pathway maps were identified using the 
software package Pathway Assist. A minimum of 3 interacting genes is the required criteria for creation of a map (Software: 
Pathway Assist™ Stratagene).BMC Cancer 2005, 5:74 http://www.biomedcentral.com/1471-2407/5/74
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correspondingly only 20 probe sets increased in actino-
mycin D treated cells (Figure 1). The biochemical func-
tions of these down-regulated genes include cell
proliferation, cell cycle, programmed cell death and
metabolism (Figure 2). These findings provide a first clue
of the complex biological processes affected by the drug
both on a quantitative and on a qualitative basis.
Doxorubicin achieves clinical response rates of 20% to
26% and represents one of the most effective chemother-
apeutic agents among the available drugs, which are used
in first line single drug therapies [43]. Doxorubicin
inhibits topoisomerase II and causes DNA damage, at
least partially in a p53-dependent manner [44]. There was
a marked count of probesets affected by doxorubicin. The
regulated sequences include genes involved in cell prolif-
eration and cell cycle (Figure 2). This finding is in line
with the results of others and may represent the signature
profile of doxorubicin induced gene expression [8].
Understanding the exact molecular events and the resist-
ance mechanisms induced by anticancer therapy would
provide new opportunities for pathway-based rational
therapy and for drug development [9,10]. To elucidate the
mechanisms and the degree of the molecular response we
analyzed the intracellular pathways, which are influenced
by doxorubicin in a fibrosarcoma cell line. We identified
five different pathways, which include at least three genes
with altered expression levels. Four of these pathways reg-
ulate apoptosis (Figure 4).
Apoptosis in response to cancer therapy proceeds through
activation of the core apoptotic machinery including the
receptor and the mitochondrial signaling pathway [45-
47]. The relative contribution of the receptor and mito-
chondrial pathways to drug-induced apoptosis has been a
subject of controversial discussion. While a number of ini-
tial studies suggested that cancer therapy-triggered apop-
tosis involves activation of the CD95 receptor/ligand
system, compelling evidence subsequently indicated that
the majority of cytotoxic drugs initiate cell death by trig-
gering the mitochondrial signaling pathway [48]. The data
of our study support either possibilities. Doxorubicin
showed influences on genes involved in the extrinsic as
well as on genes involved in the intrinsic pathway.
One major extrinsic apoptogenic pathway is the cyto-
chrome c/Apaf-1/caspase-9 dependent pathway (Figure
4). We found cytochrome c, Apaf-1, caspase-3, caspase-6,
caspase-8 and caspase-9 up-regulated by doxorubicin. The
release of mitochondrial apoptogenic proteins, such as
cytochrome c, into the cytoplasm leads to Apaf-1 depend-
ent activation of caspase-9, which is a key event in this
pathway. Especially Apaf-1, a member of the NOD-family
(nucleotide binding oligomerization domain) is known
to play a central role in the cell death machinery. Its
expression has been demonstrated to be involved in
several cell death pathways. Furthermore Apaf-1 is an acti-
vator of caspases [49,50]. Apaf-1 inactivation leads to
chemoresistance for example in malignant melanoma
cells [51]. Additionally, the anti-apoptotic factor Bcl-2, a
direct antagonist of p53 and cytochrome c, was down-reg-
ulated. Various pro- and anti-apoptotic Bcl-2 family pro-
teins regulate the permeability of the mitochondrial outer
membrane, and DNA damage triggers apoptosis through
the down-regulation of anti-apoptotic Bcl-2. Yeh and
Pusztai demonstrated that Bcl-2 could be responsible for
the resistance to apoptosis induced by cytotoxic drugs.
Thus the down-regulation of Bcl-2 should sensitize cells to
doxorubicin [52-54]. These results might indicate that
doxorubicin initiates cell death of HT1080 cells by activat-
ing the cytochrome c/Apaf-1/caspase-9 dependent path-
way. Our results confirm the results of others showing
that doxorubicin triggers Bcl-2 down-regulation, cyto-
chrome c release from mitochondria and the activation of
caspases-3 and 9 [55-57]. Doxorubicin changed the
expression of several caspases. These findings are in agree-
ment with recently published data about different cas-
pases acting as key factors in doxorubicin mediated cell
death [58-62]. Caspases are the key effector molecules in
most forms of apoptotic cell death and represent the level,
where the intrinsic and the extrinsic apoptotic pathway
converge [62]. Additionally they interact with other non-
caspases apoptotic pathways [63]. Caspases are catego-
rized into initiator (caspase-2, -8, -9, -10) and effector cas-
pases (caspase-3, -6, -7) [64]. Doxorubicin induced the
expression of caspases-1, -3, -6, -8 and -9. Caspase-6 cleav-
age may feed back to the receptor pathway by cleaving cas-
pase-8 [65,66]. Within the caspases pathway we found
two additional genes down-regulated, LMNB1 and ARH-
GDIB (Figure 5). Little is known about the function of
these proteins. They might play a role in a number of
processes related to metastases [67,68]. LMNB1 and ARH-
GDIB are effectors of the caspases-3 and -6, respectively,
and are thus also involved in the apoptotic Fas signaling
pathway (Figure 6). There are hints that the extrinsic path-
way is connected with the sensitivity and with the resist-
ance of tumor cells towards cytotoxic treatment.
Chemotherapeutic treatment led to an increase in CD95L
expression, which triggered the receptor pathway. In sup-
port of this concept, increased levels of CD95L were
observed in many different tumor cell lines [9,32,69-71].
Our results indicated that the pathway is influenced by
doxorubicin. In addition to the expression of the two
genes LMNB1 and ARHGDIB, the expression of the death
domain containing protein FADD, PTPN13 (protein tyro-
sine phosphatase non-receptor type 13) and the expres-
sion of the caspases-8, -3 and -6 were regulated.
Furthermore we found decreased expression levels of the
Fas-associated apoptosis inhibitory molecules FAIM andBMC Cancer 2005, 5:74 http://www.biomedcentral.com/1471-2407/5/74
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FAIM2, what is another indication for the activation of the
Fas pathway by doxorubicin.
In the intrinsic pathway, various apoptosis inducing sig-
nals directly or indirectly change mitochondria mem-
brane permeability and cause release of mitochondrial
intermembrane proteins, including cytochrome c [72]. In
the cytoplasm, pro-caspase-9, Apaf-1 and cytochrome-c
assemble to form the apoptosome [73,74]. In an ATP-
dependent process, procaspase-9 is cleaved in the apopto-
some. Activated caspase-9 then cleaves and activates down
stream caspases, such as caspase-3. Down-stream of the
caspase-8 or caspase-9 activation cascade the intrinsic and
extrinsic apoptosis pathways converge in the executioner
caspases-3, -6 and -7 [75,76]. Once activated, the
executioner caspases are responsible for the proteolytic
cleavage of a broad range of cellular proteins resulting in
cell death [73,74].
In addition to the activation of several different apoptosis
regulating pathways doxorubicin activates also pathways
that activate proliferation, differentiation and inhibition
of apoptosis. The EGF signaling pathway regulates cell
proliferation and transformation. Analyzing this pathway
we found altered expression of the genes Rasa1 (decreased
levels), STAT1 and STAT3 (increased levels). STAT1 has
been implicated in modulating pro- and anti-apoptotic
genes following several stress-induced responses and
therefore is able to act as a tumor suppressor [77]. STAT3
suppresses expression of pro-inflammatory mediators in
tumor cells. Blocking STAT3 in tumor cells induces the
expression of pro-inflammatory cytokines and chemok-
ines that activate innate immunity and dendritic cells
[78]. For example STAT3 protects prostatic cancer cells
from apoptosis induced by T lymphocytes [79]. In human
neuroblastoma cells doxorubicin leads to STAT3 activa-
tion that results in apoptosis inhibition [80].
The pleiotropic cytokine IL-6 exhibits many physiological
functions, including host defense, bone metabolism and
acute phase responses. A variety of malignant tumors
express IL-6. In multiple myeloma cells IL-6 inhibits
apoptosis induced by serum starvation, dexamethasone,
and Fas [81]. In pre-B cells, however, IL-6 is important for
differentiation and apoptosis. A further study demon-
strated that IL-6 is responsible for drug resistance and anti-
apoptotic effects in prostatic cancer cells. The anti-apop-
totic ability of IL-6 is associated with expression of the Bcl-
2 family proteins [82]. Interestingly, the IL-6 mediated
inhibition of apoptosis is associated with up-regulation of
Bcl-2, which is independent of STAT3 [83]. We found
increased IL-6 levels after doxorubicin treatment. How-
ever there were increased levels of STAT3 in combination
with decreased levels of Bcl-2 at the same time. In conclu-
sion the pathway-analyses offer doxorubicin mediated
apoptotic and anti-apoptotic mechanisms side by side.
The concept that anticancer therapies primarily act by trig-
gering apoptosis has been challenged, since a consistent
link between the ability of tumor cells to undergo
apoptosis in vitro and their susceptibility to anticancer
therapy in vivo is not essential. Therefore, pathways lead-
ing to non-apoptotic cell death, e.g. necrosis or yet unclas-
sified forms of cell death, may mediate the response to
cytotoxic therapy [84,85]. Also, caspase independent
apoptosis has been found to be induced by anticancer
drugs in some cells [86-88]. Furthermore, recent findings
have shown that caspase inhibitors do not protect cancer
cells from death by cytotoxic agents, but may switch drug-
induced apoptosis to an alternative default death e.g.
sensescence [89].
Understanding these events and the diverse modes of
tumor cell death may provide new opportunities for
pathway-based rational therapy and for drug develop-
ment [90].
The drug response is of course dependent on their concen-
tration. Further studies including different sarcoma cells,
drug concentrations and time responses will strengthened
the knowledge about the chemotherapy resistance in the
very heterogeneous soft tissue sarcomas.
Conclusion
The analysis of gene expression patterns and regulated
pathways, which result from treatment with cytostatic
agents, could provide a new basis for tumor therapy. This
study demonstrates that HT1080-fibrosarcoma cells
reveal a specific response pattern of apoptosis-related fac-
tors on mRNA level, which depends on the used cytostatic
drug. The response rates on the gene expression level, i.e.
the number of genes regulated by the drugs, correlate to
the clinical effectiveness of the drugs. In addition we
found a large number of differentially expressed genes
whose biochemical functions include cell proliferation,
cell cycle regulators, cell growth, metabolism and others.
These findings provide an insight into the complex bio-
logical processes affected by the drug and may represent
the signature profiles of drug induced gene expression.
The knowledge of the genes affected by the drugs in
HT1080 fibrosarcoma cells will help to understand the
diverse modes of cell death in other soft tissue sarcomas
in response to cytotoxic therapies.
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